Targeting IL-10 family cytokines for the treatment of human diseases

Cold Spring Harbor Perspectives in Biology

Volumn 11, Issue 2, 2019, Pages

  Wang, Xiaoting ^a   Wong, Kit ^b   Ouyang, Wenjun ^a   Rutz, Sascha ^b  

^a AMGEN INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10;

AUTOIMMUNE DISEASE; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; NEOPLASM; PHYSIOLOGY;

AUTOIMMUNE DISEASES; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-10; NEOPLASMS;

EID: 85060906306     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a028548     Document Type: Article

References (261)

1. Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E, la Torre de A, Lasfar A, Kotenko SV. 2010. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother 59: 1059–1071.
2. Adris S, Klein S, Jasnis M, Chuluyan E, Ledda M, Bravo A, Carbone C, Chernajovsky Y, Podhajcer O. 1999. IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T-cell-mediated tu-tu-mor rejection in the context of a systemic Th2 response. Gene Ther 6: 1705–1712. mor
3. Aggarwal S, Xie MH, Maruoka M, Foster J, Gurney AL. 2001. Acinar cells of the pancreas are a target of interleukin-22. J Interferon Cytokine Res 21: 1047–1053.
4. Alanärä T, Karstila K, Moilanen T, Silvennoinen O, Isomäki P. 2010. Expression of IL-10 family cytokines in rheumatoid arthritis: Elevated levels of IL-19 in the joints. Scand J Rheumatol 39: 118–126.
5. Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, Tsujikawa T, Kitoh K, Kim-Mitsuyama S, Takayanagi A, et al. 2005. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic sub-epithelial myofibroblasts. Gastroenterology 129: 969–984.
6. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. 2006. Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80: 4501–4509.
7. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk H-D, Döcke WD. 1998. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: A new therapeutic approach. J Clin Invest 101: 783–794.
8. Asadullah K, Sterry W, Volk H-D. 2003. Interleukin-10 ther-apy—Review of a new approach. Pharmacol Rev 55: 241– 269.
9. Avitabile S, Odorisio T, Madonna S, Eyerich S, Guerra L, Eyerich K, Zambruno G, Cavani A, Cianfarani F. 2015. Interleukin-22 promotes wound repair in diabetes by improving keratinocyte pro-healing functions. J Invest Dermatol 135: 2862–2870.
10. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS; Acute Pancreatitis Classification Working Group. 2013. Classification of acute pancreatitis—2012: Revision of the Atlanta classification and definitions by international consensus. Gut 62: 102–111.
11. Benbouziane B, Ribelles P, Aubry C, Martin R, Kharrat P, Riazi A, Langella P, Bermúdez-Humarán LG. 2013. Development of a stress-inducible controlled expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. J Biotechnol 168: 120–129.
12. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, Carollo S, Eagan M, Foster D, Haldeman BA, Hammond A, et al. 2001. Interleukin 20: Discovery, receptor identification, and role in epidermal function. Cell 104: 9–19.
13. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F. 2005. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174: 3695– 3702.
14. Boniface K, Guignouard E, Pedretti N, Garcia M, Delwail A, Bernard FX, Nau F, Guillet G, Dagregorio G, Yssel H, et al. 2007. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 150: 407–415.
15. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. 2015. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627–1639.
16. Bosanquet DC, Harding KG, Ruge F, Sanders AJ, Jiang WG. 2012. Expression of IL-24 and IL-24 receptors in human wound tissues and the biological implications of IL-24 on keratinocytes. Wound Repair Regen 20: 896–903.
17. Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. 2005. The global burden of diabetic foot disease. Lancet 366: 1719–1724.
18. Braganza JM, Lee SH, McCloy RF, McMahon MJ. 2011. Chronic pancreatitis. Lancet 377: 1184–1197.
19. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diebold J, Diepolder H, Adler B, Auernhammer CJ, et al. 2005. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 289: G960–G968.
20. Brem H, Tomic-Canic M. 2007. Cellular and molecular basis of wound healing in diabetes. J Clin Invest 117: 1219– 1222.
21. + T cells are associated with therapeutic Trichuris trichiura infection in an ulcerative colitis patient. Sci Transl Med 2: 60ra88.
22. Burkart C, Arimoto KI, Tang T, Cong X, Xiao N, Liu YC, Kotenko SV, Ellies LG, Zhang DE. 2013. Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10. EMBO Mol Med 5: 1035–1050.
23. Buruiana FE, Solà I, Alonso-Coello P. 2010. Recombinant human interleukin 10 for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 119: CD005109.
24. Cannella B, Gao YL, Brosnan C, Raine CS. 1996. IL-10 fails to abrogate experimental autoimmune encephalomyelitis. J Neurosci Res 45: 735–746.
25. Cannella F, Scagnolari C, Selvaggi C, Stentella P, Recine N, Antonelli G, Pierangeli A. 2014. Interferon λ1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women. Med Microbiol Immunol 203: 177–184.
26. Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G. 1993. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 β in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 178: 2207– 2211.
27. Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, Retter MW, Hill P, Chada S, Grimm EA. 2002. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 168: 6041–6046.
28. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, Lucian L, Geissler R, Brodie S, Kimball AB, et al. 2006. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203: 2577– 2587.
29. Chen DS, Mellman I. 2017. Elements of cancer immunity and the cancer-immune set point. Nature 541: 321–330.
30. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonne-mann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA. 1995. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154: 5492– 5499.
31. Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J, Van Deventer S, Ferguson A, Des-reumaux P, Forbes A, et al. 2001. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn’s disease. Gut 49: 42–46.
32. Corvaisier M, Delneste Y, Jeanvoine H, Preisser L, Blanchard S, Garo E, Hoppe E, Barré B, Audran M, Bouvard B, et al. 2012. IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation. PloS Biol 10: e1001395.
33. Creery WD, Diaz-Mitoma F, Filion L, Kumar A. 1996. Differential modulation of B7–1 and B7–2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Eur J Immunol 26: 1273–1277.
34. Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y, Mhashilkar A, Parker K, Vukelja S, Richards D, et al. 2005. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: A phase I study. Mol Ther 11: 149–159.
35. Dambacher J, Beigel F, Zitzmann K, Heeg MHJ, Göke B, Diepolder HM, Auernhammer CJ, Brand S. 2008. The role of interleukin-22 in hepatitis C virus infection. Cytokine 41: 209–216.
36. D’Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. 1993. Interleukin 10 (IL-10) inhibits human lymphocyte interferon λ-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178: 1041–1048.
37. da Rocha LF, Duarte ALBP, Dantas AT, Mariz HA, Pitta IDR, Galdino SL, Pitta MGDR. 2012. Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. J Rheumatol 39: 1320– 1325.
38. Dejaco C, Reinisch W, Lichtenberger C, Waldhoer T, Kuhn I, Tilg H, Gasche C. 2000. In vivo effects of recombinant human interleukin-10 on lymphocyte phenotypes and leukocyte activation markers in inflammatory bowel disease. J Investig Med 48: 449–456.
39. del Carmen S, de Moreno de LeBlanc A, Perdigon G, Bastos Pereira V, Miyoshi A, Azevedo V, LeBlanc JG. 2011. Evaluation of the anti-inflammatory effect of milk fermented by a strain of IL-10-producing Lactococcus lactis using a murine model of Crohn’s disease. J Mol Microbiol Biotechnol 21: 138–146.
40. del Carmen S, Martín Rosique R, Saraiva T, Zurita-Turk M, Miyoshi A, Azevedo V, de Moreno de LeBlanc A, Langella P, Bermúdez-Humarán LG, LeBlanc JG. 2014. Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model. J Clin Gastroenterol 48 (Suppl 1): S12–S17.
41. de Waal-Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. 1991a. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174: 1209– 1220.
42. de Waal-Malefyt R, Haanen J, Spits H, Roncarolo MG, Velde Te A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE. 1991b. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174: 915–924.
43. Doll F, Schwager K, Hemmerle T, Neri D. 2013. Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse. Arthritis Res Ther 15: R138.
44. Drouault S, Corthier G, Ehrlich SD, Renault P. 1999. Survival, physiology, and lysis of Lactococcus lactis in the digestive tract. Appl Environ Microbiol 65: 4881–4886.
45. Dudakov JA, Hanash AM, Jenq RR, Young LF, Ghosh A, Singer NV, West ML, Smith OM, Holland AM, Tsai JJ, et al. 2012. Interleukin-22 drives endogenous thymic regeneration in mice. Science 336: 91–95.
46. Durbin RK, Kotenko SV, Durbin JE. 2013. Interferon induction and function at the mucosal surface. Immunol Rev 255: 25–39.
47. Eidenschenk C, Rutz S, Liesenfeld O, Ouyang W. 2014. Role of IL-22 in microbial host defense. Curr Top Microbiol Immunol 380: 213–236.
48. Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sauane M, Dash R, Grant S, Dent P, Curiel DT, Sarkar D, et al. 2009. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther 8: 391– 400.
49. + T cells without de novo infiltration from secondary lymphoid organs. Cancer Res 72: 3570–3581.
50. Engelhardt KR, Shah N, Faizura-Yeop I, Kocacik Uygun DF, Frede N, Muise AM, Shteyer E, Filiz S, Chee R, Elawad M, et al. 2013. Clinical outcome in IL-10-and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol 131: 825–830.
51. Falanga V. 2005. Wound healing and its impairment in the diabetic foot. Lancet 366: 1736–1743.
52. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, et al. 2016. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375: 1946–1960.
53. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, et al. 2000. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119: 1473– 1482.
54. Feng D, Kong X, Weng H, Park O, Wang H, Dooley S, Gershwin ME, Gao B. 2012a. Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology 143: 188–198.e7.
55. Feng D, Park O, Radaeva S, Wang H, Yin S, Kong X, Zheng M, Zakhari S, Kolls JK, Gao B. 2012b. Interleukin-22 ameliorates cerulein-induced pancreatitis in mice by inhibiting the autophagic pathway. Int J Biol Sci 8: 249–257.
56. Ferrara JLM, Levine JE, Reddy P, Holler E. 2009. Graft-ver-sus-host disease. Lancet 373: 1550–1561.
57. Fiorentino DF, Bond MW, Mosmann TR. 1989. Two types of mouse T helper cell. IV: Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170: 2081–2095.
58. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A. 1991. IL-10 inhibits cytokine production by activated macrophages. J Immunol 147: 3815–3822.
59. Fox BA, Sheppard PO, O’Hara PJ. 2009. The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-λ family. PloS ONE 4: e4933.
60. Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D, et al. 2008. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 40: 1319–1323.
61. Franke A, McGovern DPB, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, et al. 2010. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 42: 1118–1125.
62. Franz M, Doll F, Grün K, Richter P, Köse N, Ziffels B, Schubert H, Figulla HR, Jung C, Gummert J, et al. 2015. Targeted delivery of interleukin-10 to chronic cardiac allo-graft rejection using a human antibody specific to the extra domain A of fibronectin. Int J Cardiol 195: 311–322.
63. Fredlund P, Hillson J, Gray T, Shemanski L, Dimitrova D, Srinivasan S. 2015. Peginterferon Lambda-1a is associated with a low incidence of autoimmune thyroid disease in chronic hepatitis C. J Interferon Cytokine Res 35: 841– 843.
64. Friborg J, Levine S, Chen C, Sheaffer AK, Chaniewski S, Voss S, Lemm JA, McPhee F. 2013. Combinations of λ interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimi-crob Agents Chemother 57: 1312–1322.
65. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. 2009. Interferon-λ is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 284: 20869–20875.
66. Galeazzi M, Bazzichi L, Sebastiani GD, Neri D, Garcia E, Ravenni N, Giovannoni L, Wilton J, Bardelli M, Baldi C, et al. 2014. A phase IB clinical trial with Dekavil (F8-IL10), an immunoregulatory “armed antibody” for the treatment of rheumatoid arthritis, used in combination wiIh methotrexate. Isr Med Assoc J 16: 666.
67. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399–401.
68. Geremia A, Arancibia-Cárcamo CV, Fleming MPP, Rust N, Singh B, Mortensen NJ, Travis SPL, Powrie F. 2011. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 208: 1127–1133.
69. Gibbert K, Schlaak JF, Yang D, Dittmer U. 2013. IFN-α subtypes: Distinct biological activities in anti-viral therapy. Br J Pharmacol 168: 1048–1058.
70. H 22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 130: 1344–1354.
71. Glocker E-O, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, et al. 2009. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361: 2033–2045.
72. Gottlieb AB, Krueger JG, Sandberg Lundblad M, Göthberg M, Skolnick BE. 2015. First-in-human, phase 1, randomized, dose-escalation trial with recombinant anti-IL-20 monoclonal antibody in patients with psoriasis. PloS ONE 10: e0134703.
73. + T cells. J Exp Med 184: 19–29.
74. + T cells. J Immunol 160: 3188–3193.
75. Guenterberg KD, Grignol VP, Raig ET, Zimmerer JM, Chan AN, Blaskovits FM, Young GS, Nuovo GJ, Mundy BL, Lesinski GB, et al. 2010. Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. Mol Cancer Ther 9: 510–520.
76. Guilloteau K, Paris I, Pedretti N, Boniface K, Juchaux F, Huguier V, Guillet G, Bernard F-X, Lecron J-C, Morel F. 2010. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1α, and TNF-α recapitulates some features of psoriasis. J Immunol 184: 5263–5270.
77. Hagenbaugh A, Sharma S, Dubinett SM, Wei SH, Aranda R, Cheroutre H, Fowell DJ, Binder S, Tsao B, Locksley RM, et al. 1997. Altered immune responses in interleukin 10 transgenic mice. J Exp Med 185: 2101–2110.
78. Hanash AM, Dudakov JA, Hua G, O’Connor MH, Young LF, Singer NV, West ML, Jenq RR, Holland AM, Kappel LW, et al. 2012. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity 37: 339–350.
79. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, et al. 2002. Maintenance infliximab for Crohn’s disease: The ACCENT I randomised trial. Lancet 359: 1541–1549.
80. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. 2006. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: The CLASSIC-I trial. Gastroenterology 130: 323–33; quiz 591.
81. He M, Liang P. 2010. IL-24 transgenic mice: In vivo evidence of overlapping functions for IL-20, IL-22, and IL-24 in the epidermis. J Immunol 184: 1793–1798.
82. Hill T, Krougly O, Nikoopour E, Bellemore S, Lee-Chan E, Fouser LA, Hill DJ, Singh B. 2013. The involvement of interleukin-22 in the expression of pancreatic β cell regenerative Reg genes. Cell Regen (Lond) 2: 2.
83. Hou W, Wang X, Ye L, Zhou L, Yang Z-Q, Riedel E, Ho WZ. 2009. Lambda interferon inhibits human immunodefi-ciency virus type 1 infection of macrophages. J Virol 83: 3834–3842.
84. Hsu YH, Li HH, Hsieh MY, Liu MF, Huang KY, Chin LS, Chen PC, Cheng HH, Chang MS. 2006. Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum 54: 2722–2733.
85. Hsu YH, Hsieh PP, Chang MS. 2012. Interleukin-19 blockade attenuates collagen-induced arthritis in rats. Rheumatology (Oxford) 51: 434–442.
86. Huan C, Kim D, Ou P, Alfonso A, Stanek A. 2016. Mechanisms of interleukin-22’s beneficial effects in acute pancreatitis. World J Gastrointest Pathophysiol 7: 108–116.
87. Huang EH, Park JC, Appelman H, Weinberg AD, Banerjee M, Logsdon CD, Schmidt AM. 2006. Induction of inflammatory bowel disease accelerates adenoma formation in Min +/-mice. Surgery 139: 782–788.
88. Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, Hedl M, Zhang W, O’Connor W, Murphy AJ, et al. 2012. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491: 259–263.
89. Huhn RD, Radwanski E, O’Connell SM, Sturgill MG, Clarke L, Cody RP, Affrime MB, Cutler DL. 1996. Pharmacoki-netics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 87: 699–705.
90. Huhn RD, Radwanski E, Gallo J, Affrime MB, Sabo R, Gonyo G, Monge A, Cutler DL. 1997. Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clin Pharmacol Ther 62: 171–180.
91. Hunt DWC, Boivin WA, Fairley LA, Jovanovic MM, King DE, Salmon RA, Utting OB. 2006. Ultraviolet B light stimulates interleukin-20 expression by human epithelial keratinocytes. Photochem Photobiol 82: 1292–1300.
92. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, Nojima Y. 2005. Expression of interleukin-22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine. Arthritis Rheum 52: 1037–1046.
93. Innocentin S, Guimarães V, Miyoshi A, Azevedo V, Langella P, Chatel JM, Lefèvre F. 2009. Lactococcus lactis expressing either Staphylococcus aureus fibronectin-binding protein AorListeria monocytogenes internalin A can efficiently internalize and deliver DNA in human epithelial cells. Appl Environ Microbiol 75: 4870–4878.
94. Itoh K, Hirohata S. 1995. The role of IL-10 in human B cell activation, proliferation, and differentiation. J Immunol 154: 4341–4350.
95. Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Danielsson A, Verbaan H, et al. 2005. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 128: 1805–1811.
96. Jeffcoate WJ, Harding KG. 2003. Diabetic foot ulcers. Lancet 361: 1545–1551.
97. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. 1995. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 11: 2477–2486.
98. Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB. 1996. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci 93: 9160–9165.
99. Jiang R, Wang H, Deng L, Hou J, Shi R, Yao M, Gao Y, Yao A, Wang X, Yu L, et al. 2013. IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer 13: 59.
100. Justa S, Zhou X, Sarkar S. 2014. Endogenous IL-22 plays a dual role in arthritis: Regulation of established arthritis via IFN-γ responses. PloS ONE 9: e93279.
101. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. 2010. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 130: 1373–1383.
102. lo ) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med 208: 1027–1040.
103. Kasama T, Strieter RM, Lukacs NW, Burdick MD, Kunkel SL. 1994. Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 152: 3559–3569.
104. Kaser A, Zeissig S, Blumberg RS. 2010. Inflammatory bowel disease. Annu Rev Immunol 28: 573–621.
105. Ki SH, Park O, Zheng M, Morales-Ibanez O, Kolls JK, Batal-ler R, Gao B. 2010. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: Role of signal transducer and activator of transcription 3. Hepatology 52: 1291–1300.
106. Kirchberger S, Royston DJ, Boulard O, Thornton E, Fran-chini F, Szabady RL, Harrison O, Powrie F. 2013. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 210: 917– 931.
107. Kobold S, Völk S, Clauditz T, Küpper NJ, Minner S, Tufman A, Düwell P, Lindner M, Koch I, Heidegger S, et al. 2013. Interleukin-22 is frequently expressed in small-and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells. J Thorac Oncol 8: 1032–1042.
108. Koenig KF, Groeschl I, Pesickova SS, Tesar V, Eisenberger U, Trendelenburg M. 2012. Serum cytokine profile in patients with active lupus nephritis. Cytokine 60: 410–416.
109. Kofoed K, Skov L, Zachariae C. 2015. New drugs and treatment targets in psoriasis. Acta Derm Venereol 95: 133–139.
110. Kolumam G, Wu X, Lee WP, Hackney JA, Zavala-Solorio J, Gandham V, Danilenko DM, Arora P, Wang X, Ouyang W. 2017. IL-22R ligands IL-20, IL-22, and IL-24 promote wound healing in diabetic db/db mice. PloS ONE 12: e0170639.
111. Konya V, Mjösberg J. 2015. Innate lymphoid cells in graft-versus-host disease. Am J Transplant 15: 2795–2801.
112. Kopp T, Lenz P, Bello-Fernandez C, Kastelein RA, Kupper TS, Stingl G. 2003. IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: Evidence for enhanced cutaneous immunity. J Immunol 170: 5438–5444.
113. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Don-nelly RP. 2003. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69–77.
114. Kragstrup TW, Otkjaer K, Holm C, Jørgensen A, Hokland M, Iversen L, Deleuran B. 2008. The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine 41: 16–23.
115. Kreis S, Philippidou D, Margue C, Rolvering C, Haan C, Dumoutier L, Renauld JC, Behrmann I. 2007. Recombi-Recombi-nant interleukin-24 lacks apoptosis-inducing properties in melanoma cells. PloS ONE 2: e1300. nant
116. Kreis S, Philippidou D, Margue C, Behrmann I. 2008. IL-24: A classic cytokine and/or a potential cure for cancer? J Cell Mol Med 12: 2505–2510.
117. Kühn R, Löhler J, Rennick D, Rajewsky K, Muller W. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263–274.
118. Lasfar A, de laTorre A, Abushahba W, Cohen-Solal KA, Castaneda I, Yuan Y, Reuhl K, Zloza A, Raveche E, Laskin DL, et al. 2016. Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth. Oncotarget 7: 49259–49267.
119. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJ, van der Poll T. 2000. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 165: 2783–2789.
120. Leipe J, Schramm MA, Grunke M, Baeuerle M, Dechant C, Nigg AP, Witt MN, Vielhauer V, Reindl CS, Schulze-Koops H, et al. 2011. Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis. Ann Rheum Dis 70: 1453–1457.
121. + cells are depleted in actively inflamed colitis tissue. Mucosal Immunol 7: 124–133.
122. Levy Y, Brouet JC. 1994. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 93: 424–428.
123. Li J, Chen J, Kirsner R. 2007. Pathophysiology of acute wound healing. Clin Dermatol 25: 9–18.
124. Li W, Lewis-Antes A, Huang J, Balan M, Kotenko SV. 2008. Regulation of apoptosis by type III interferons. Cell Prolif 41: 960–979.
125. Li W, Danilenko DM, Bunting S, Ganesan R, Sa S, Ferrando R, Wu TD, Kolumam GA, Ouyang W, Kirchhofer D. 2009. The serine protease marapsin is expressed in stratified squamous epithelia and is up-regulated in the hyper-proliferative epidermis of psoriasis and regenerating wounds. J Biol Chem 284: 218–228.
126. 1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer 46: 180–190.
127. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203: 2271–2279.
128. Lin FC, Young HA. 2014. Interferons: Success in anti-viral immunotherapy. Cytokine Growth Factor Rev 25: 369– 376.
129. Lindemans CA, Calafiore M, Mertelsmann AM, O’Connor MH, Dudakov JA, Jenq RR, Velardi E, Young LF, Smith OM, Lawrence G, et al. 2015. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature 528: 560–564.
130. Llorente L, Richaud-Patin Y, García-Padilla C, Claret E, Ja-kez-Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L, Alarcón-Segovia D, Wijdenes J, et al. 2000. Clinical and biologic effects of anti-interleukin-10 monoclo-nal antibody administration in systemic lupus erythema-tosus. Arthritis Rheum 43: 1790–1800.
131. Loser K, Apelt J, Voskort M, Mohaupt M, Balkow S, Schwarz T, Grabbe S, Beissert S. 2007. IL-10 controls ultraviolet-induced carcinogenesis in mice. J Immunol 179: 365–371.
132. Ma H-L, Liang S, Li J, Napierata L, Brown T, Benoit S, Senices M, Gill D, Dunussi-Joannopoulos K, Collins M, et al. 2008. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 118: 597–607.
133. Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y. 2015. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett 367: 103–107.
134. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM. 2006. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131: 1887–1898.
135. Marijnissen RJ, Koenders MI, Smeets RL, Stappers MHT, Nickerson-Nutter C, Joosten LAB, Boots AMH, van den Berg WB. 2011. Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation. Arthritis Rheum 63: 2939– 2948.
136. Martin R, Chain F, Miquel S, Natividad JM, Sokol H, Verdu EF, Langella P, Bermúdez-Humarán LG. 2014. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation. Hum Vaccin Immunother 10: 1611–1621.
137. McGee HM, Schmidt BA, Booth CJ, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA, Horsley V. 2013. IL-22 promotes fibroblast-mediated wound repair in the skin. J Invest Dermatol 133: 1321–1329.
138. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. 2005. Biological activity of interleukins-28 and-29: Comparison with type I interferons. Cytokine 31: 109–118.
139. Michaels J, Churgin SS, Blechman KM, Greives MR, Aarabi S, Galiano RD, Gurtner GC. 2007. db/db mice exhibit severe wound-healing impairments compared with other murine diabetic strains in a silicone-splinted excisional wound model. Wound Repair Regen 15: 665–670.
140. Miller DM, Klucher KM, Freeman JA, Hausman DF, Fon-tana D, Williams DE. 2009. Interferon λ as a potential new therapeutic for hepatitis C. Ann NY Acad Sci 1182: 80–87.
141. Miyoshi A, Jamet E, Commissaire J, Renault P, Langella P, Azevedo V. 2004. A xylose-inducible expression system for Lactococcus lactis. FEMS Microbiol Lett 239: 205–212.
142. Montes-Torres A, Llamas-Velasco M, Pérez-Plaza A, Sola-no-López G, Sánchez-Pérez J. 2015. Biological treatments in atopic dermatitis. J Clin Med 4: 593–613.
143. Moore K, de Waal M, Coffman R, O’Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683–765.
144. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, Staeheli P. 2008. Interferon-λ contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PloS Pathog 4: e1000151.
145. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, Sorgeloos F, Ehl S, Mayer D, Kochs G, et al. 2010. Λ interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 84: 5670–5677.
146. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Pli-mack ER, et al. 2015. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373: 1803–1813.
147. Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, et al. 2014. A randomized phase 2b study of peginterferon λ-1a for the treatment of chronic HCV infection. J Hepatol 61: 1238–1246.
148. Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, Blaisdell S, Basham B, Dai J, Grein J, et al. 2011. IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell 20: 781–796.
149. Munneke JM, Björklund AT, Mjösberg JM, Garming-Legert K, Bernink JH, Blom B, Huisman C, van Oers MHJ, Spits H, Malmberg K-J, et al. 2014. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood 124: 812–821.
150. Nagelkerken L, Blauw B, Tielemans M. 1997. IL-4 abrogates the inhibitory effect of IL-10 on the development of experimental allergic encephalomyelitis in SJL mice. Int Immunol 9: 1243–1251.
151. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, et al. 2016. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol 34: 3562–3569.
152. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D. 2001. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 19: 239–247.
153. Nestle FO, Kaplan DH, Barker J. 2009. Psoriasis. N Engl J Med 361: 496–509.
154. Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T, Ramon M, Bergman R, Krueger JG, Guttman-Yassky E. 2009. IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 123: 1244–1252.e2.
155. Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M, Iwakura Y, Aiba S, Yamaya M. 2007. IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 178: 5086–5098.
156. O’Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. 2008. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 223: 114–131.
157. Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, Fujita T. 2007. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 282: 7576–7581.
158. O’Shea JJ, Kanno Y, Chan AC. 2014. In search of magic bullets: The golden age of immunotherapeutics. Cell 157: 227–240.
159. Ota N, Wong K, Valdez PA, Zheng Y, Crellin NK, Diehl L, Ouyang W. 2011. IL-22 bridges the lymphotoxin pathway with the maintenance of colonic lymphoid structures during infection with Citrobacter rodentium. Nat Immunol 12: 941–948.
160. Otkjaer K, Kragballe K, Funding AT, Clausen JT, Noerby PL, Steiniche T, Iversen L. 2005. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br J Dermatol 153: 911–918.
161. Ouyang W. 2010. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine Growth Factor Rev 21: 435–441.
162. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. 2011. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29: 71–109.
163. Pan H, Hong F, Radaeva S, Gao B. 2004. Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol 1: 43–49.
164. Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S, Ki SH, Yoo SH, Dooley S, Wang FS, et al. 2011. In vivo consequences of liver-specific interleukin-22 expression: Implications for human liver disease progression. Hepatology 54: 252–261.
165. Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S, Folgori A, Rehermann B. 2012. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 56: 2060–2070.
166. Pelczar P, Witkowski M, Perez LG, Kempski J, Hammel AG, Brockmann L, Kleinschmidt D, Wende S, Haueis C, Bedke T, et al. 2016. A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease. Science 354: 358–362.
167. Pène J, Chevalier S, Preisser L, Vénéreau E, Guilleux MH, Ghannam S, Molès JP, Danger Y, Ravon E, Lesaux S, et al. 2008. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 180: 7423–7430.
168. Perera GK, Ainali C, Semenova E, Hundhausen C, Barinaga G, Kassen D, Williams AE, Mirza MM, Balazs M, Wang X, et al. 2014. Integrative biology approach identifies cytokine targeting strategies for psoriasis. Sci Transl Med 6: 223ra22.
169. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. 2004. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22: 929–979.
170. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, Lehr HA, Hirth S, Weigmann B, Wirtz S, et al. 2009. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 206: 1465–1472.
171. Radaeva S, Sun R, Pan HN, Hong F, Gao B. 2004. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39: 1332–1342.
172. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. 2015. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372: 2521–2532.
173. Rømer J, Hasselager E, Nørby PL, Steiniche T, Thorn Clausen J, Kragballe K. 2003. Epidermal overexpression of interleukin-19 and-20 mRNA in psoriatic skin disap-disap-pears after short-term treatment with cyclosporine a or calcipotriol. J Invest Dermatol 121: 1306–1311. pears
174. Rosenblum IY, Johnson RC, Schmahai TJ. 2002. Preclinical safety evaluation of recombinant human interleukin-10. Regul Toxicol Pharmacol 35: 56–71.
175. Rousset F, Garcia E, Defrance T, Péronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J. 1992. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci 89: 1890–1893.
176. Rousset F, Peyrol S, Garcia E, Vezzio N, Andujar M, Gri-maud JA, Banchereau J. 1995. Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4. Int Immunol 7: 1243– 1253.
177. + T cell-depen-dent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26: 623–637.
178. Rutz S, Ouyang W. 2011. Regulation of interleukin-10 and interleukin-22 expression in T helper cells. Curr Opin Immunol 23: 605–612.
179. Rutz S, Ouyang W. 2016. Regulation of interleukin-10 expression. Adv Exp Med Biol 941: 89–116.
180. H 17 cells. Nat Immunol 12: 1238–1245.
181. Rutz S, Eidenschenk C, Ouyang W. 2013. IL-22, not simply a Th17 cytokine. Immunol Rev 252: 116–132.
182. Rutz S, Wang X, Ouyang W. 2014. The IL-20 subfamily of cytokines—From host defence to tissue homeostasis. Nat Rev Immunol 14: 783–795.
183. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, Kasman I, Winer J, Modrusan Z, Danilenko DM, et al. 2007. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178: 2229–2240.
184. Sabat R, Ouyang W, Wolk K. 2013. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 13: 21–38.
185. Sakurai N, Kuroiwa T, Ikeuchi H, Hiramatsu N, Maeshima A, Kaneko Y, Hiromura K, Nojima Y. 2008. Expression of IL-19 and its receptors in RA: Potential role for synovial hyperplasia formation. Rheumatology (Oxford) 47: 815– 820.
186. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, PRECISE 1 Study Investigators. 2007. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 357: 228–238.
187. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P, Ustekinumab Crohn’s Disease Study. 2008. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 135: 1130–1141.
188. Saraiva M, O’Garra A. 2010. The regulation of IL-10 production by immune cells. Nat Rev Immunol 10: 170–181.
189. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. 2006. Antitumor activity of IFN-λ in murine tumor models. J Immunol 176: 7686–7694.
190. Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Lebedeva IV, Dent P, Pestka S, Fisher PB. 2003. MDA-7/IL-24: Novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev 14: 35–51.
191. Saxena A, Khosraviani S, Noel S, Mohan D, Donner T, Hamad ARA. 2015. Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine 74: 27–34.
192. Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P, et al. 2000. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Crohn’s Disease IL-10 Cooperative Study Group. Gastroenterology 119: 1461–1472.
193. Schuetze N, Schoeneberger S, Mueller U, Freudenberg MA, Alber G, Straubinger RK. 2005. IL-12 family members: Differential kinetics of their TLR4-mediated induction by Salmonella enteritidis and the impact of IL-10 in bone marrow-derived macrophages. Int Immunol 17: 649–659.
194. Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, Trachsel E. 2009. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocyto-kine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 11: R142.
195. Schwager K, Bootz F, Imesch P, Kaspar M, Trachsel E, Neri D. 2011. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model. Hum Reprod 26: 2344–2352.
196. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB. 1998. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66: 5224–5231.
197. Šenolt L, Leszczynski P, Dokoupilová E, Göthberg M, Valencia X, Hansen BB, Cañete JD. 2015. Efficacy and safety of anti-interleukin-20 monoclonal antibody in patients with rheumatoid arthritis: A randomized phase IIa trial. Arthritis Rheumatol 67: 1438–1448.
198. Sfikakis PP. 2010. The first decade of biologic TNF antagonists in clinical practice: Lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 11: 180– 210.
199. Sharma P, Allison JP. 2015. The future of immune checkpoint therapy. Science 348: 56–61.
200. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. 2017. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168: 707–723.
201. Shen H, Goodall JC, Hill Gaston JS. 2009. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 60: 1647–1656.
202. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schluts-meyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, et al. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63–68.
203. Shim JO, Hwang S, Yang HR, Moon JS, Chang JY, Ko JS, Park SS, Kang GH, Kim WS, Seo JK. 2013. Interleukin-10 receptor mutations in children with neonatal-onset Crohn’s disease and intractable ulcerating enterocolitis. Eur J Gastroenterol Hepatol 25: 1235–1240.
204. Singer AJ, Clark RA. 1999. Cutaneous wound healing. N Engl J Med 341: 738–746.
205. Sommereyns C, Paul S, Staeheli P, Michiels T. 2008. IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PloS Pathog 4: e1000017.
206. Sonnenberg GF, Fouser LA, Artis D. 2011. Border patrol: Regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 12: 383– 390.
207. Sosman JA, Verma A, Moss S, Sorokin P, Blend M, Bradlow B, Chachlani N, Cutler D, Sabo R, Nelson M, et al. 2000. Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: Evidence for decreased platelet production. Br J Haematol 111: 104–111.
208. Steen HC, Gamero AM. 2010. Interferon-λ as a potential therapeutic agent in cancer treatment. J Interferon Cytokine Res 30: 597–602.
209. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. 2000. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289: 1352–1355.
210. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E. 2003. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 21: 785–789.
211. + T cells resulting in a failure to lyse tumor cells. Blood 93: 1634–1642.
212. Stenderup K, Rosada C, Worsaae A, Dagnaes-Hansen F, Steiniche T, Hasselager E, Iversen LF, Zahn S, Wöldike H, Holmberg HL, et al. 2009. Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol 160: 284–296.
213. Sturlan S, Oberhuber G, Beinhauer BG, Tichy B, Kappel S, Wang J, Rogy MA. 2001. Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis 22: 665–671.
214. Su ZZ, Madireddi MT, Lin JJ, Young CS, Kitada S, Reed JC, Goldstein NI, Fisher PB. 1998. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci 95: 14400–14405.
215. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, Blumberg RS, Xavier RJ, Mizoguchi A. 2008. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 118: 534–544.
216. Sun DP, Yeh CH, So E, Wang LY, Wei TS, Chang MS, Hsing CH. 2013. Interleukin (IL)-19 promoted skin wound healing by increasing fibroblast keratinocyte growth factor expression. Cytokine 62: 360–368.
217. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, et al. 2009. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 41: 1100–1104.
218. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, et al. 2009. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105–1109.
219. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, et al. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798–801.
220. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Nou-reddin M, Rotman Y, Liang TJ. 2012. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 142: 978–988.
221. Tilg H, Van Montfrans C, van den Ende A, Kaser A, van Deventer SJH, Schreiber S, Gregor M, Ludwiczek O, Rutgeerts P, Gasche C, et al. 2002. Treatment of Crohn’s disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ. Gut 50: 191– 195.
222. Tohyama M, Hanakawa Y, Shirakata Y, Dai X, Yang L, Hi-rakawa S, Tokumaru S, Okazaki H, Sayama K, Hashimoto K. 2009. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol 39: 2779–2788.
223. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, et al. 2005. Intratumoral injection of INGN 241, a nonreplicat-ing adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): Biologic outcome in advanced cancer patients. Mol Ther 11: 160–172.
224. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443–2454.
225. Topalian SL, Drake CG, Pardoll DM. 2015. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 27: 450–461.
226. Trachsel E, Bootz F, Silacci M, Kaspar M, Kosmehl H, Neri D. 2007. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther 9: R9.
227. Uzé G, Monneron D. 2007. IL-28 and IL-29: Newcomers to the interferon family. Biochimie 89: 729–734.
228. van Deventer SJ, Elson CO, Fedorak RN; Crohn’s Disease Study Group. 1997. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease. Gastroenterology 113: 383–389.
229. Vicari AP, Trinchieri G. 2004. Interleukin-10 in viral diseases and cancer: Exiting the labyrinth? Immunol Rev 202: 223–236.
230. Wang Z, Yang L, Jiang Y, Ling ZQ, Li Z, Cheng Y, Huang H, Wang L, Pan Y, Wang Z, et al. 2011. High fat diet induces formation of spontaneous liposarcoma in mouse adipose tissue with overexpression of interleukin 22. PloS ONE 6: e23737.
231. Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, Zhang J, Lesch J, Lee WP, Ross J, et al. 2014. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 514: 237–241.
232. Weiss G, Bogdan C, Hentze MW. 1997. Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13. J Immunol 158: 420–425.
233. Whitaker EL, Filippov VA, Duerksen-Hughes PJ. 2012. Interleukin 24: Mechanisms and therapeutic potential of an anti-cancer gene. Cytokine Growth Factor Rev 23: 323– 331.
234. Willems F, Marchant A, Delville JP, Gerard C, Delvaux A, Velu T, de Boer M, Goldman M. 1994. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 24: 1007– 1009.
235. Williams HC. 2005. Clinical practice. Atopic dermatitis. N Engl J Med 352: 2314–2324.
236. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, Sorror ML, Horowitz MM, Bolwell B, Rizzo JD, et al. 2011. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 29: 2230–2239.
237. Witte K, Gruetz G, Volk H-D, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K. 2009. Despite IFN-λ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: Implications for therapeutic applications of these cytokines. Genes Immun 10: 702–714.
238. Wogensen L, Lee MS, Sarvetnick N. 1994. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice. J Exp Med 179: 1379–1384.
239. Wolk K, Sabat R. 2006. Interleukin-22: A novel T-and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 17: 367–380.
240. Wolk K, Kunz S, Asadullah K, Sabat R. 2002. Cutting edge: Immune cells as sources and targets of the IL-10 family members? J Immunol 168: 5397–5402.
241. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. 2004. IL-22 increases the innate immunity of tissues. Immunity 21: 241–254.
242. Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K, Volk HD, Sterry W, Sabat R. 2006. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: A potential role in psoriasis. Eur J Immunol 36: 1309–1323.
243. Wolk K, Haugen HS, Xu W, Witte E, Waggie K, Anderson M, Baur Vom E, Witte K, Warszawska K, Philipp S, et al. 2009a. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-λ are not. J Mol Med 87: 523–536.
244. Wolk K, Witte E, Warszawska K, Schulze-Tanzil G, Witte K, Philipp S, Kunz S, Döcke WD, Asadullah K, Volk HD, et al. 2009b. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: A novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 39: 3570–3581.
245. Xavier RJ, Podolsky DK. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427–434.
246. Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, Wood WI, Goddard AD, Gurney AL. 2000. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2–4 and IL-22R. J Biol Chem 275: 31335–31339.
247. Xing WW, Zou MJ, Liu S, Xu T, Wang JX, Xu DG. 2011. Interleukin-22 protects against acute alcohol-induced hepatotoxicity in mice. Biosci Biotechnol Biochem 75: 1290–1294.
248. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, et al. 2006. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116: 1310–1316.
249. Yu LZ, Wang HY, Yang SP, Yuan ZP, Xu FY, Sun C, Shi RH. 2013. Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis. World J Gastroenterol 19: 2638–2649.
250. Yu H, Lee H, Herrmann A, Buettner R, Jove R. 2014. Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer 14: 736–746.
251. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. 2007. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 27: 647–659.
252. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA. 2008. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29: 947–957.
253. Zenewicz LA, Yin X, Wang G, Elinav E, Hao L, Zhao L, Flavell RA. 2013. IL-22 deficiency alters colonic micro-biota to be transmissible and colitogenic. J Immunol 190: 5306–5312.
254. Zhang L, Li JM, Liu XG, Ma DX, Hu NW, Li YG, Li W, Hu Y, Yu S, Qu X, et al. 2011. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J Clin Immunol 31: 606–614.
255. Zhang L, Li Y-G, Li Y-H, Qi L, Liu X-G, Yuan C-Z, Hu N-W, Ma D-X, Li Z-F, Yang Q, et al. 2012. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PloS ONE 7: e31000.
256. Zheng XX, Steele AW, Hancock WW, Stevens AC, Nickerson PW, Roy-Chaudhury P, Tian Y, Strom TB. 1997. A non-cytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol 158: 4507–4513.
257. H 17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 648–651.
258. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, Abbas AR, Modrusan Z, Ghilardi N, de Sauvage FJ, et al. 2008. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 14: 282–289.
259. + T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol Immunother 61: 1965–1975.
260. Zitzmann K, Brand S, Baehs S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer CJ. 2006. Novel interferon-λs induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 344: 1334–1341.
261. Zurita-Turk M, del Carmen S, Santos ACG, Pereira VB, Cara DC, Leclercq SY, de LeBlanc AD, Azevedo V, Chatel JM, LeBlanc JG, et al. 2014. Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis. BMC Biotechnol 14: 73.